Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Capital Raising Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - A$80 million fully underwritten equity raising (ASX:IMM)

Immutep Limited ACN 009 237 889 (ASX: IMM) (Immutep or Company) is pleased to announce that it has launched an equity raising (Offer) through a fully underwritten pro rata accelerated nonrenoun...read more

Immutep - Trading Halt (ASX:IMM)

To view the announcement, download the attached PDF.

Immutep - Charles River Laboratories to run IMP761 Toxicology Study (ASX:IMM)

Appointment of Charles River Laboratories ("Charles River") to run Immutep’s preclinical toxicology study evaluating the safety and toxicity of IMP761 Form...read more

Immutep - Publication of Abstracts for ASCO 2023 Annual Meeting (ASX:IMM)

New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma Dee...read more

Immutep - 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial (ASX:IMM)

SYDNEY, AUSTRALIA – 25 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developi...read more

Immutep - Promising New Data in 1st line NSCLC from INSIGHT-003 Trial (ASX:IMM)

Efti plus standard-of-care anti-PD-1 therapy and doublet chemotherapy in 1st line non-small cell lung cancer is well tolerated and continues to show promising initial signals of...read more

Immutep - Excellent initial Overall Survival Benefit in 1st line NSCLC (ASX:IMM)

Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase...read more

Immutep - FDA supportive of Efti registrational trial in lung cancer (ASX:IMM)

SYDNEY, AUSTRALIA – 16 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nov...read more

Immutep - Change of Director's Interest Notice - R Howard (ASX:IMM)

To view the notice, download the attached PDF.

Immutep - Approval to start Efti & Bavencio trial in urothelial cancer (ASX:IMM)

Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO®...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - March 2023 (ASX:IIQ)

Progress on EXO-NET® commercialisation with Academia and Industry INOVIQ presented on EXO-NET and exosomes to the Preterm Birth International Collaborative #PREBIC Aus...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Initiation of integrated Phase II/III AIPAC-003 trial evaluating eftilagimod alpha (efti) and paclitaxel in HER2-neg/low metastatic breast cancer and triple-negative breast cancer ...read more

Immutep to announce new TACTI-002 data at ASCO 2023 (ASX:IMM)

Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA – 27 April 2023 – Immutep L...read more

Immutep appoints Dr Florian Vogl as Chief Medical Officer (ASX:IMM)

SYDNEY, AUSTRALIA – 26 April 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune...read more

Viewing: 121 - 135 of 200 Previous | Next